HRT shortages are affecting both trans women and menopausal women, with oestrogen patches and gels running low in several countries while the political climate in the United States has created new fears about insurance coverage and prescription access. If your medication feels less certain than it did a year ago, you are reading the situation correctly, and there are things worth knowing and doing.
Why are oestrogen patches and gels in short supply?
Shortages in hormone therapies, particularly oestrogen patches and some gel formulations, have been building for a while. The reasons are a familiar tangle: manufacturing bottlenecks, supply chain disruption, demand that has grown faster than production has scaled, and in some countries regulatory delays that slow the licensing of alternative brands. The result is that pharmacies are running out, prescriptions are being switched without warning, and people who have been stable on a particular formulation for years are suddenly told they need to use something different.
For trans women, this is not a minor administrative inconvenience. Oestrogen is not a lifestyle supplement; it is the medication that keeps the body functioning in the way it needs to, maintains bone density, supports cardiovascular health, and underpins wellbeing in ways that are hard to overstate. Switching formulation mid-treatment is sometimes necessary, but it can shift absorption, alter hormone levels, and require a period of rebalancing that many people find destabilising. The anxiety that comes with not knowing whether your prescription will be filled next month is real and it deserves to be named.
What is actually happening with HRT access in the US?
The United States has its own specific crisis layered on top of the global supply picture. The current federal political environment has created genuine uncertainty about insurance coverage for gender-affirming medications, and that uncertainty is doing harm even where no ban has yet been enacted. When people do not know whether their insurer will continue to cover their hormones, many stop refilling in time, reduce their dose to make supplies last, or avoid engaging with the healthcare system at all out of fear. All of those responses carry real medical risk.
The difference between fear of what might happen and what has actually changed matters here. Executive orders and political directives have targeted gender-affirming care in various ways, particularly for people under 19, but the legal landscape for adult trans women accessing oestrogen through private insurance is still being contested and varies significantly by state. Some states have enacted protections; others have moved in the opposite direction. The situation is not static, and it is worth knowing specifically what your state's position is rather than assuming the worst applies to you right now, while also not assuming you are protected when you may not be.
Does the shortage affect menopausal women and trans women differently?
In terms of the physical shortage, the medications are often the same. Oestrogen patches used in menopause management and those used in feminising hormone therapy are frequently identical products, so a shortage hits both groups from the same depleted stock. What differs is the political framing and the advocacy response. Menopausal women have louder institutional voices in many countries: gynaecology societies, menopause clinics, established patient advocacy groups. Trans women accessing the same medication through gender-affirming care pathways sometimes find that their need is treated as more negotiable, more political, more dispensable.
That asymmetry is worth naming because it affects how people are treated at the pharmacy counter, how quickly shortages in gender-affirming care get flagged at a policy level, and how much media coverage the two groups receive when the same medication runs out. A trans woman whose oestrogen patch prescription cannot be filled is experiencing the same medical problem as a menopausal woman in the same position, and the solution is the same: find an equivalent formulation, maintain continuity of care, and document the disruption. The problem is that trans women are more likely to encounter a pharmacist or prescriber who treats the disruption as less urgent.
What can you actually do if your prescription is affected?
The first thing is not to ration or skip doses without medical input. I hear from people who cut patches in half, extend the interval between doses, or simply stop when they cannot get a refill, reasoning that something is better than nothing or that the disruption will be short. The problem is that hormone levels drop, the body notices, and the effects, on mood, on sleep, on bone density over time, on cardiovascular health, compound quickly. If you are struggling to access your medication, the right move is to contact whoever manages your prescription and ask them to flag the shortage formally and explore alternatives.
Alternatives do exist. If your oestrogen patch brand is unavailable, an equivalent patch from a different manufacturer is usually bioequivalent and can be switched without a significant period of adjustment, though your levels should be checked after the switch. Oestrogen gel, oral oestrogen, and injectable oestrogen are all options, each with different absorption profiles and monitoring needs. What you want to avoid is an unmonitored switch made in a panic because the pharmacy was out of stock; what you want is a planned switch with a blood test a few weeks later to confirm your levels are where they need to be.
For people in the United States worried about insurance coverage, a few things are worth knowing. Patient advocacy organisations such as the National Center for Transgender Equality track state-level policy changes and can tell you what protections currently exist in your state. If your insurer denies a claim, the denial can be appealed, and appeals succeed more often than people expect. Telehealth prescribers who work specifically with trans people are operating across many states and in some cases can bridge gaps in local access. And for people outside the US who are worried about the political climate spreading, the answer right now is to document your prescriptions, ensure you have copies of your records, and stay connected to community information.
The anxiety itself is the other problem
I want to say something directly about the fear, because I think it is doing harm that is distinct from the practical shortage. When people do not know whether their medication will be there next month, when they read news that is often deliberately alarming, when they see lawmakers treating their healthcare as a political bargaining chip, the anxiety that results is not a side effect to be managed. It is a rational response to a genuinely unstable situation, and it has its own impact on health and wellbeing that is separate from whatever is actually happening to their prescription.
Medication anxiety in this context tends to compound. A person who is worried about running out skips a dose to save it, their levels drop, their mood and sleep suffer, they feel less able to advocate for themselves, they engage less with the system that could help them, and the shortage feels worse than it is. Breaking that cycle means getting accurate information about your specific situation rather than the most alarming version of the general situation, making a plan with whoever prescribes for you, and, where possible, staying connected to people who are navigating the same thing.
Trans women have been dealing with medication uncertainty for a long time, longer than the current political moment. That is not a reason to be calm about conditions that are genuinely harmful; it is a reason to know that community knowledge, shared workarounds, and collective advocacy have got people through before and will again.
A note on the broader picture
Oestrogen patches and gels have been used safely for decades. The evidence base for feminising hormone therapy in trans women is well established, endorsed by the World Health Organisation, WPATH's Standards of Care 8, and the Endocrine Society guidelines. The current moment of shortage and political pressure does not change what the medication is or what it does; it changes only the ease of access, and ease of access is something that can be fought for and improved.
If you are outside the United States and worried about whether the restrictions there will spread to your country, the honest answer is that it is worth watching, worth engaging with your elected representatives about, and worth supporting the organisations that track and challenge these changes. But the legal and regulatory frameworks in most countries are currently different, and your prescriber and your pharmacy are the right first call if your supply is disrupted, not a general assumption that access is over.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a Gender Specialist, Medical Educator, and Advocate. She is the founder of GenderGP and writes about gender diversity, trans healthcare, and the lives around them.